Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol , No 18S ( Supplement), :
© 2009 American Society of Clinical Oncology

Return to article

XELOX-Placebo + FOLFOX-Placebo XELOX-Bev + FOLFOX-Bev PFS general approach 8.0 9.4 HR 0.83 (97.5% CI 0.72–0.95), p=0.0023 PFS on treatment approach 7.9 10.4 HR 0.63 (97.5% CI 0.52–0.75), p<0.0001 PFS based on IRC dataset 8.6 11.1 HR 0.70 (97.5% CI 0.58–0.83), p<0.0001

Return to article